ORF73-null murine gammaherpesvirus 68 reveals roles for mLANA and p53 in virus replication.
Gammaherpesviruses establish lifelong, latent infections in host lymphocytes, during which a limited subset of viral gene products facilitates maintenance of the viral episome. Among the gamma-2-herpesvirus (rhadinovirus) subfamily, this includes expression of the conserved ORF73-encoded LANA proteins. We previously demonstrated by loss-of-function mutagenesis that the murine gammaherpesvirus 68 (MHV68) ORF73 gene product, mLANA, is required for the establishment of latency following intranasal inoculation of mice (N. J. Moorman, D. O. Willer, and S. H. Speck, J. Virol. 77:10295-10303, 2003). mLANA-deficient viruses also exhibited a defect in acute virus replication in the lungs of infected mice. The latter observation led us to examine the role of mLANA in productive viral replication. We assessed the capacity of mLANA-deficient virus (73.Stop) to replicate in cell culture at low multiplicities of infection (MOIs) and found that 73.Stop growth was impaired in murine fibroblasts but not in Vero cells. A recombinant virus expressing an mLANA-green fluorescent protein (GFP) fusion revealed that mLANA is expressed throughout the virus replication cycle. In addition, 73.Stop infection of murine fibroblasts at high MOIs was substantially more cytotoxic than infection with a genetically repaired marker rescue virus (73.MR), a phenotype that correlated with enhanced kinetics of viral gene expression and increased activation of p53. Notably, augmented cell death, viral gene expression, and p53 induction were independent of viral DNA replication. Expression of a mLANA-GFP fusion protein in fibroblasts correlated with both reduced p53 stabilization and reduced cell death following treatment with p53-inducing agonists. In agreement, accentuated cell death associated with 73.Stop infection was reduced in p53-deficient murine embryonic fibroblasts. Additionally, replication of 73.Stop in p53-deficient cells was restored to levels comparable to those of 73.MR. More remarkably, the absence of p53 led to an overall delay in replication for both 73.Stop and 73.MR viruses, which correlated with delayed viral gene expression, indicating a role for p53 in MHV68 replication. Consistent with these findings, the expression of replication-promoting viral genes was positively influenced by p53 overexpression or treatment with the p53 agonist etoposide. Overall, these data demonstrate the importance of mLANA in MHV68 replication and suggest that LANA proteins limit the induction of cellular stress responses to regulate the viral gene expression cascade and limit host cell injury.
Forrest
J Craig
JC
Department of Microbiology and immunology, Emory Vaccine Center, Emory University School of Medicine, 1462 Clifton Rd., Atlanta, GA 30322, USA.
Paden
Clinton R
CR
Allen
Robert D
RD
Collins
Julie
J
Speck
Samuel H
SH
D000818:Animals; D000951:Antigens, Neoplasm / Q000502:physiology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D005347:Fibroblasts / Q000378:metabolism; D018142:Gammaherpesvirinae; D015967:Gene Expression Regulation, Viral; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D058965:MART-1 Antigen; D051379:Mice; D041681:NIH 3T3 Cells; D009363:Neoplasm Proteins / Q000502:physiology*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D014709:Vero Cells; D014764:Viral Proteins / Q000235:genetics* / Q000502:physiology; D014779:Virus Replication
D000951:Antigens, Neoplasm; D058965:MART-1 Antigen; C548667:MLANA protein, human; C548668:Mlana protein, mouse; D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53; D014764:Viral Proteins; D049452:Green Fluorescent Proteins
J Virol. 2004 Aug;78(15):8068-77
15254178
Virology. 2005 Oct 25;341(2):271-83
16102793
Apoptosis. 2002 Aug;7(4):321-8
12101391
J Virol. 1995 Nov;69(11):6697-704
7474079
Gene. 2000 Apr 18;247(1-2):1-15
10773440
J Exp Med. 1998 Jun 15;187(12):1941-51
9625754
Nature. 1970 Aug 15;227(5259):680-5
5432063
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11321-6
8876134
Cell. 1997 Mar 7;88(5):593-602
9054499
Genes Dev. 2000 Aug 15;14(16):2015-27
10950866
Oncogene. 2002 Dec 5;21(55):8379-87
12466958
J Virol. 2003 Jul;77(13):7308-18
12805429
Nature. 1999 Dec 23-30;402(6764):889-94
10622254
J Virol. 2006 Jan;80(2):697-709
16378973
Cancer Cell. 2002 Jul;2(1):55-65
12150825
J Clin Invest. 2006 Mar;116(3):735-42
16498502
Virology. 2007 Sep 1;365(2):250-9
17477952
PLoS Pathog. 2005 Sep;1(1):e10
16201011
Biochem Cell Biol. 1997;75(4):337-49
9493956
J Immunol. 2000 Jul 15;165(2):1074-81
10878386
Methods. 2001 Dec;25(4):402-8
11846609
J Virol. 2003 Aug;77(15):8310-21
12857900
Cancer Surv. 1986;5(2):389-404
2946407
J Virol. 2001 Feb;75(3):1487-506
11152521
Oncogene. 2005 Apr 18;24(17):2899-908
15838523
J Gen Virol. 2003 Dec;84(Pt 12):3405-16
14645921
J Clin Invest. 2005 Mar;115(3):642-52
15765147
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3805-10
15738413
J Virol. 2004 Jun;78(12):6585-94
15163750
J Virol. 2000 Aug;74(16):7451-61
10906198
J Virol. 1997 Aug;71(8):5894-904
9223479
Science. 2004 Feb 13;303(5660):1010-4
14963330
J Biol Chem. 1996 Feb 16;271(7):3534-40
8631958
J Virol. 2003 May;77(10):5731-9
12719566
J Virol. 2004 Oct;78(19):10336-47
15367600
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2821-6
16477038
Virology. 2006 Apr 25;348(1):19-34
16455125
J Virol. 2006 Aug;80(16):7965-75
16873253
J Virol. 2006 Nov;80(21):10802-12
16956952
Oncogene. 1992 May;7(5):935-42
1349164
Nature. 1991 Jan 31;349(6308):429-31
1671528
J Virol. 2000 Aug;74(15):6964-74
10888635
Cell Death Differ. 2006 Jun;13(6):941-50
16601750
Oncogene. 2005 Apr 18;24(17):2796-809
15838516
J Clin Invest. 1997 Nov 15;100(10):2606-10
9366576
J Virol. 1997 Apr;71(4):3146-60
9060678
J Gen Virol. 1992 Dec;73 ( Pt 12):3275-9
1469366
J Virol. 2001 Feb;75(4):1870-8
11160686
J Virol. 2007 Feb;81(4):1912-22
17121789
J Virol. 2003 May;77(10):5911-25
12719584
Cell. 2004 Feb 20;116(4):487-9
14980216
Antimicrob Agents Chemother. 1998 Jan;42(1):170-2
9449280
J Virol. 2006 Sep;80(17):8390-401
16912290
J Virol. 2003 Oct;77(19):10295-303
12970414
J Virol. 2005 Mar;79(5):3127-38
15709032
Cancer Cell. 2007 Feb;11(2):175-89
17292828
J Virol. 2003 Oct;77(19):10488-503
12970434
EMBO J. 2006 Sep 20;25(18):4284-92
16957780
J Virol. 1999 Apr;73(4):3273-83
10074181
J Virol. 2006 Dec;80(24):11946-59
17005668
Nature. 2006 Nov 30;444(7119):638-42
17136094
J Virol. 1998 Mar;72(3):2033-9
9499057
J Virol. 2004 Mar;78(5):2169-78
14963113
J Gen Virol. 1999 Oct;80 ( Pt 10):2737-40
10573168
J Virol. 2004 Aug;78(15):8359-71
15254208
Microbiol Mol Biol Rev. 2002 Jun;66(2):179-202
12040123
Genes Dev. 1998 Oct 1;12(19):3008-19
9765203
J Virol. 2002 Jun;76(12):6244-56
12021358
J Virol. 1996 Oct;70(10):6775-80
8794315
Nature. 2000 Nov 16;408(6810):307-10
11099028
J Gen Virol. 2005 Mar;86(Pt 3):561-74
15722515
J Virol. 1985 Nov;56(2):558-70
2997476
J Virol. 2000 Feb;74(4):2029-37
10644377
J Biol Chem. 2005 Feb 4;280(5):3862-74
15525642
J Biol Chem. 2005 Aug 26;280(34):30336-41
15964848
J Virol. 1999 Jun;73(6):5110-22
10233974
Nat Med. 2000 Oct;6(10):1121-7
11017143
Nature. 2006 Nov 30;444(7119):633-7
17136093
Gene. 2002 May 15;290(1-2):19-34
12062798
Genes Dev. 1993 Apr;7(4):535-45
8384579